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Background: Liver fibrosis is characterized by the excessive formation and accumulation of matrix proteins as a result
of wound healing in the liver. A main event during fibrogenesis is the activation of the liver resident quiescent hepatic
stellate cell (qHSC). Recent studies suggest that reversion of the activated HSC (aHSC) phenotype into a quiescent-like
phenotype could be a major cellular mechanism underlying fibrosis regression in the liver, thereby offering new
therapeutic perspectives for the treatment of liver fibrosis. Whether human HSCs have the ability to undergo a similar
reversion in phenotype is currently unknown. The aim of the present study is to identify experimental conditions that
can revert the in vitro activated phenotype of primary human HSCs and consequently to map the molecular events
associated with this reversion process by gene expression profiling.
Results: We find that epidermal growth factor (EGF) and fibroblast growth factor 2 (FGF2) synergistically
downregulate the expression of ACTA2 and LOX in primary human aHSCs. Their combination with oleic acid,
palmitic acid, and retinol further potentiates a more quiescent-like phenotype as demonstrated by the abundant
presence of retinyl ester-positive intra-cytoplasmic lipid droplets, low expression levels of activation markers, and
a reduced basal as well as cytokine-stimulated proliferation and matrix metalloproteinase activity. Gene
expression profiling experiments reveal that these in vitro reverted primary human HSCs (rHSCs) display an
intermediary phenotype that is distinct from qHSCs and aHSCs. Interestingly, this intermediary phenotype is
characterized by the increased expression of several previously identified signature genes of in vivo inactivated
mouse HSCs such as CXCL1, CXCL2, and CTSS, suggesting also a potential role for these genes in promoting a
quiescent-like phenotype in human HSCs.
Conclusions: We provide evidence for the ability of human primary aHSCs to revert in vitro to a transitional state
through synergistic action of EGF, FGF2, dietary fatty acids and retinol, and provide a first phenotypic and
genomic characterization of human in vitro rHSCs.
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In response to injury, tissue can heal and restore its
normal function through a controlled sequence of
events known as wound healing. However, when the
insult is of chronic nature, it can impair the wound
healing response and subsequently develop into tissue
fibrosis, a condition characterized by the excessive ac-
cumulation of matrix proteins and associated with
severe morbidity and mortality [1]. Different cellular
sources, including tissue-specific fibroblasts, bone* Correspondence: lvgrunsv@vub.ac.be
1Liver Cell Biology Lab, Vrije Universiteit Brussel (VUB), Laarbeeklaan 103, 1090
Brussels, Belgium
Full list of author information is available at the end of the article
© 2015 El Taghdouini et al. This is an Open A
License (http://creativecommons.org/licenses/
medium, provided the original work is proper
creativecommons.org/publicdomain/zero/1.0/marrow-derived progenitor cells, pericytes, and epi-
thelial cells, have been suggested to give rise to myofi-
broblasts, the major source of extracellular matrix
(ECM) components in the fibrotic organ [2]. In the
liver, however, the resident hepatic stellate cell (HSC)
has unambiguously been identified as the predominant
source of myofibroblasts, irrespective of the under-
lying disease etiology [3].
In the normal liver, quiescent HSCs (qHSCs) reside in a
virtual space (of Disse) between the hepatocytes and liver
sinusoidal endothelial cells and are characterized by the
abundance of cytoplasmic lipid droplets containing up to
80 % of the total vitamin A body reserve [4]. Besides their
well-known role in the regulation of retinoid and ECMccess article distributed under the terms of the Creative Commons Attribution
by/4.0), which permits unrestricted use, distribution, and reproduction in any
ly credited. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
Table 1 Clinical characteristics of the HSC donors
Donor Healthy status Age Gender Ischemia time
L4 Healthy 12 years Female 16 h 30 min
L8 Healthy 1 day Male 4 h 40 min
L10 Healthy 7 months Female 5 h 20 min
L11 Healthy 7 days Male 4 h 25 min
L12 FH 13 years Male 1 h 30 min
FH familial hypercholesterolemia
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sinusoidal blood flow and stimulate angiogenesis [5, 6]. Fol-
lowing chronic liver injury, qHSCs undergo a process of
activation, during which they transdifferentiate into cells
with a fibrogenic, myofibroblast-like phenotype character-
ized by the loss of vitamin A-containing lipid droplets,
increased smooth muscle actin (ACTA2) expression, and
an augmentation in ECM production and secretion [4, 7].
Initially, this activation process was considered to be
unidirectional while the principal ability of the fibrotic liver
to revert to a normal state upon cessation of injury [8] was
mainly attributed to the clearance of activated HSCs
(aHSCs) that undergo apoptosis [9, 10]. However, different
studies strongly imply that at least in rodents, the activated
phenotype of HSCs can be modulated and reverted to a
quiescent-like state, both in vitro [11, 12] and in vivo
[13, 14]. The identification of aHSCs as the main source
of ECM in the fibrotic liver in conjunction with recent
work showing that HSC inactivation could drive fibrosis
regression opens new therapeutic perspectives. Indeed,
identifying and understanding the molecular events gov-
erning the reversion of an aHSC will be helpful in effi-
ciently targeting liver fibrosis. Although convincingly
shown in rodent HSCs, inactivating conditions for human
primary HSCs have barely been investigated. In the
present study, we aimed at identifying experimental
conditions that can induce a reversion of the activated
human HSC phenotype and at mapping the molecular
events associated with this process.
We find that epidermal growth factor (EGF) and fibro-
blast growth factor 2 (FGF2) act synergistically to down-
regulate the expression of ACTA2 and lysyl oxidase (LOX)
in primary human HSCs. The combined effect is further
potentiated by dietary fatty acids and retinol to reach levels
of expression that are similar to those measured in freshly
isolated, non-cultured human qHSCs. Further, this cocktail
induces a quiescent-like phenotype as demonstrated by the
acquisition of retinyl ester-containing cytoplasmic lipid
droplets and a low proliferation rate. Gene expression
profiling of human primary qHSCs and in vitro aHSCs
and reverted HSCs (rHSCs) reveals many additional pro-
fibrogenic genes to be downregulated in rHSCs. However,
despite their phenotype, the overall expression profile of
rHSCs is not similar to that of qHSCs and differs from
that of aHSCs, but shows increased expression of previ-
ously identified in vivo inactivated mouse HSC (iaHSC)
signature genes [13, 15].
Results
EGF and FGF2 act synergistically with dietary fatty acids
and retinol to revert the culture activated phenotype of
human HSCs
Human HSCs are isolated by density gradient centrifuga-
tion from the non-parenchymal cell fraction of healthyliver donors (Table 1) and seeded on plastic culture dishes
to induce activation (Fig. 1a, b). The activated status of the
cells is assessed by their typical myofibroblastic phenotype,
the strong increase in alpha smooth muscle actin (α-
SMA) protein by immunocytochemistry (Fig. 1b) and col-
lagen type 1 alpha 1 (COL1A1) and lysyl oxidase (LOX)
expression by RT-qPCR (Fig. 1c). The aHSCs express high
protein levels of platelet-derived growth factor receptor
beta (PDGFRβ), a membrane receptor associated with
HSCs (Fig. 1d). Moreover, the cells stain positive for differ-
ent markers previously shown to be expressed by HSCs,
i.e., NCAM1, nestin, and desmin [16–19] (Fig. 1e).
We have tested different culture conditions for their abil-
ity to revert the activated phenotype of HSCs. These condi-
tions include pharmacological agents previously shown to
inhibit rodent HSC activation (i.e., TWS119, valproic acid
(VPA), valinomycin, carbonyl cyanide-p-trifluoromethoxy-
phenylhydrazone (FCCP), tin-protoporphyrin IX dichloride
(SnPP), bafilomycin (BFM), hydroxychloroquine (HCQ), 3-
methyladenine (3-MA)) (Additional file 1: Figure S1A), an
adipogenic differentiation mixture (MDI) [12] (Additional
file 1: Figure S1B), and a diverse pool of growth factors and
cytokines (data not shown). While our experiments reveal
that these agents merely induce cell death (Valinomycin,
BFM, 3-MA) in human HSCs or show limited efficacy to
inactivate the cells especially at the level of COL1A1
expression (TWS119, VPA, FCCP, SnPP, HCQ, MDI), they
also reveal that FGF2 and EGF significantly downregulate
the expression of ACTA2 or ACTA2 and LOX, respectively
(Fig. 2a). We further find that the combined effect of EGF
and FGF2 on the expression of ACTA2, COL1A1, and LOX
expression is strongly potentiated by a mixture of dietary
fatty acids (oleic acid (OA); palmitic acid (PA)) and retinol
(R) to reach levels of expression that are similar to those
measured in freshly isolated, non-cultured qHSCs (Fig. 2b),
with decreased levels of ACTA2 and COL1A1 confirmed at
the protein level (Fig. 2c). Of note, the mixture of dietary
components alone has no significant effect on activation
(Fig. 2a). HSCs reverted by this mix of growth factors and
dietary components (further referred to as reverting
medium (RM)) display a quiescent-like phenotype, charac-
terized by a thinner cell body and the presence of intra-
cytoplasmic lipid droplets (Fig. 3a). Although HSCs have
strongly reduced expression levels of activation genes as
Fig. 1 (See legend on next page.)
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Fig. 1 Isolation and culture activation of human primary HSCs. a Quiescent HSC-enriched cell layer (arrow) following an 8 % Nycodenz density
gradient centrifugation. b Light microscopic and α-SMA immunocytochemistry images of the freshly isolated, qHSC-enriched cell population and
fully culture activated HSCs (passage 4). c Log2 mRNA expression levels of COL1A1 and LOX in freshly isolated, non-plated qHSCs and aHSCs from
five different donors. In the graphs, **p < 0.01. d PDGFRβ and GAPDH protein levels in aHSCs from four donors. e Positive immunostainings for
the neural markers NCAM1, nestin, and desmin
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lipid droplet accumulation is only observable after 4 days
(Additional file 1: Figure S2). Therefore, functional analysis
and gene expression profiling were performed on cells that
were incubated with RM for at least 4 days.
In order to assess whether the in vitro reverted HSCs
(rHSCs) have the molecular machinery both to metabolize
and store vitamin A, a functional hallmark of qHSCs, weFig. 2 EGF, FGF2, retinol, palmitic acid, and oleic acid act synergistically to
human primary HSCs. a Human aHSCs were exposed to recombinant hum
combination of oleic acid (100 μM) (OA), palmitic acid (100 μM) (PA), and r
ACTA2, COL1A1, and LOX expression by RTq-PCR. Results are presented as re
expression levels of ACTA2, COL1A1, and LOX in non-cultured quiescent (q),
RM (20 ng/mL EGF, 10 ng/mL FGF2, 100 μM OA, 100 μM PA, 5 μM R) from
presented as relative fold change to aHSCs. The results presented are from
as means ± SEM. ns not significant, p≥ 0.05, *p < 0.05, **p < 0.01, ***p < 0.00
from corresponding donorsmeasured the retinyl ester auto-fluorescence at 328 nm by
fluorescence-activated cell sorting (FACS). Approximately
70 % of the aHSCs cultured in RM are UV+ (Fig. 3b), and
analysis of the rHSCs under UV light shows that the auto-
fluorescent signal co-localizes with the intra-cytoplasmic
lipid droplets, indicating that vitamin A is indeed metabo-
lized and stored inside the lipid droplets (Fig. 3b).
Although the majority of rHSCs are highly UV+, some ofnegatively regulate the expression of ACTA2, COL1A1, and LOX in
an EGF (20 ng/mL), FGF2 (10 ng/mL), a combination of both, or a
etinol (5 μM) for 5 days. Extracted RNA was processed and analyzed for
lative fold change to untreated control cells (dotted line). b mRNA
culture activated (a), and reverted (r) HSCs incubated for 5 days with
three different (corresponding) donors. The expression levels are
three to five different donors. In the graphs, the results are displayed
1. c α-SMA, COL1A1, and GAPDH protein levels in aHSCs and rHSCs
Fig. 3 EGF, FGF2, retinol, palmitic acid, and oleic acid restore a reversible, quiescent-like phenotype in culture activated human primary HSCs. a Light
microscopic and Oil Red O staining images of aHSCs and rHSCs. b FACS detection and microscopic image of the intrinsic fluorescence (at a
wavelength of ~328 nm) of all-trans retinyl esters in UV-excited aHSCs and rHSCs. The arrows highlight the intrinsic fluorescent signal of retinyl esters
inside the cytoplasmic lipid droplets. c The reversibility of the RM-induced downregulation of ACTA2, COL1A1, and LOX was assessed by washing the
cells after a 5-day incubation period, followed by an additional 2-day culture in the presence or absence of recombinant human TGFβ (10 ng/mL), in
FBS-free medium. The expression levels are presented as relative fold change to rHSCs. The results presented are from three to five different donors. In
the graphs, the results are displayed as means ± SEM. ns not significant, p≥ 0.05, *p < 0.05, **p < 0.01
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difference in ability to store vitamin A is linked to a differ-
ence in activation status, FACS-sorted UV+ and UV−
rHSCs were analyzed for the expression of activation
markers but no difference was observed (Additional file 1:
Figure S3). Interestingly, the ability of RM to revert the ac-
tivated phenotype is similarly shown in a HSC-derived
myofibroblast population isolated from a cirrhotic patient
(Additional file 1: Figure S4). To investigate whether this
induced quiescent-like state is reversible, we allowed the
cells to recover for 2 days in the absence or presence of
transforming growth factor beta (TGFβ). In the absence of
TGFβ, the cells maintain low expression levels of pro-
fibrogenic genes (Fig. 3c). However, in the presence ofTGFβ, the cells again upregulate the expression of ACTA2,
COL1A1, and LOX (Fig. 3c). A viability assay was
performed to rule out that the observed effects are related
to cytotoxic effects of RM (Additional file 1: Figure S5A).
Moreover, a 3-day recovery period with 10 % fetal bovine
serum (FBS) supplemented culture medium also signifi-
cantly increases the expression of ACTA2 and LOX in
rHSCs (Additional file 1: Figure S5B).
To evaluate whether RM can, in addition to revert,
also actively prevent the culture-induced activation of
HSCs, freshly isolated mouse qHSCs were seeded in
normal control conditions or RM optimized for mouse
HSC cultures (mRM; see “Methods”) until day 6. We
find that the cells grown in mRM maintain low
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uncultured D0 mouse qHSCs and have an intermediary
phenotype with large intra-cytoplasmic lipid droplets
(Additional file 1: Figure S6).
In vitro reverted human HSCs have a reduced
proliferation and matrix metalloproteinase activity
It is known that aHSCs functionally differ from qHSCs
by their increased proliferation, unbalanced ECM
homeostasis, and higher migratory potential [4]. There-
fore, we further investigated whether human in vitro
rHSCs functionally differ from their activated counter-
parts by comparing their proliferation (EdU incorpor-
ation), ECM degradation (in situ zymography), and
PDGF-BB-induced migration (transwell assay) (Fig. 4).
We show that RM significantly reduces the prolifera-
tion (Fig. 4a–c) and matrix metalloproteinase (MMP)
activity of human aHSCs (Fig. 4d, e). Furthermore,
while PDGF-BB and TGFβ increase proliferation and
protease activity in aHSCs, respectively, the stimulatory
effect of both growth factors is totally abrogated in
rHSCs (Fig. 4a–e). Although we note a clear difference
in basal, non-stimulated migration between aHSCs and
rHSCs (Fig. 4f ), the differences are not significant and
presumably linked to the differences in proliferation.
Moreover, PDGF-BB-induced migration was compar-
able in both groups (Fig. 4f ).
The overall gene expression profile of in vitro rHSCs is
distinct from that of aHSCs and qHSCs
To gain more insight into the gene expression changes
elicited by this transient reversion into a quiescent-like
state, the global gene expression profile of rHSCs was
assessed and compared to that of freshly isolated, non-
cultured qHSCs and culture aHSCs using the human
genome U219 arrays. We find that the global gene
expression profile of rHSCs resembles more closely that
of aHSCs than qHSCs (Fig. 5a), with 2277 (rHSC vs
aHSC) against 9122 (rHSC vs qHSC) genes expressed
at significantly different levels (Student t test, p ≤ 0.05)
(Fig. 5b). We find that many of the top upregulated
genes in rHSCs compared to aHSCs are inflammation-
related, i.e., IL-8, IL-33, IL-1β, CXCL1, CXCL2, and
CXCL6, and over 60 % of the ≥2-fold deregulated genes
in rHSCs are downregulated and include genes such as
TNNT2, SULT1E1, and ACTG2 (Fig. 5c, d). We were
further interested in identifying potential molecular pro-
cesses governing this phenotypic reversion of the activated
state. We find that although a limited number of genes
(n = 375) is at least twofold differentially regulated upon
RM exposure (Fig. 6a), around 75 % (n = 279) of these
genes are also deregulated upon activation (Fig. 6a,
Additional file 2: Table S1) and 212 genes have an ex-
pression profile that negatively correlates with changesobserved during HSC activation (Fig. 6b, c and Fig. 6e, f ).
Over 50 % of those genes are upregulated during activa-
tion and again downregulated in rHSCs (Fig. 6b, c). This
set includes many well-known pro-fibrogenic genes, i.e.,
COL5A1, ADAM12, LOXL1, ACTG2, NOTCH3, and
CRYAB, and associates with Gene Ontology (GO) terms
such as “Extracellular matrix organization,” “Actin
binding,” and “Muscle contraction” (Fig. 6d). Interest-
ingly, this set of genes is enriched for different KEGG
pathways of major importance in aHSCs, including
“Vascular smooth muscle contraction” (p value 8.28 × 10−8),
“Focal adhesion” (6.48 × 10−5), “Regulation of actin cyto-
skeleton” (9.47 × 10−5), and “ECM receptor interaction”
(2.13 × 10−3) (Fig. 6d). Another 23 % of the genes show the
opposite negative correlation, i.e., downregulated during ac-
tivation and upregulated in rHSCs (Fig. 6e, f). This set is as-
sociated with more general GO terms and enriches for
genes pertaining to “Retinol metabolism” (Fig. 6g).
In vitro reverted human HSCs upregulate the expression
of in vivo inactivated-HSC-specific markers
To determine whether human HSCs reverted to
quiescence-like by RM share characteristics with in vivo
inactivated HSCs (iaHSCs) found in the mouse liver after
recovery from experimentally induced fibrosis [13, 14], we
measured the expression of a panel of genes (n = 10)
previously identified as upregulated or specific for in vivo
iaHSCs compared to aHSCs and qHSCs [13, 15], in
aHSCs and rHSCs from three HSC donors. Although
there was inter-donor variation, we find all 10 genes to be
consistently upregulated in rHSCs (Table 2).
Discussion
A strong body of evidence suggests that upon removal
of the etiological agent, liver fibrosis can spontaneously
revert in patients with secondary biliary fibrosis [20],
hepatitis B [21] and C [22], non-alcoholic steatohepatitis
[23], and autoimmune hepatitis [24]. Recent studies in
rodent models of liver fibrosis have convincingly shown
that fibrosis regression is in part driven by the reversion
of aHSCs to quiescence-like HSCs [13, 14]. While this
ability to revert was shown both in vitro [11, 12] and
in vivo [13, 14] for rodent HSCs, it remains unknown
whether the activated phenotype of human HSCs can be
reverted as well. Moreover, the molecular mechanisms
underlying the intermediate phenotype of reverted HSCs
remain largely unknown. Therefore, our study aimed at
identifying conditions that can revert the activated status
of human HSCs and to map the molecular events associ-
ated with this phenotype reversion.
Our experiments reveal a role for EGF and FGF2 in
negatively regulating the activated phenotype of human
HSCs. The identification of EGF as a negative regulator
of HSC activation is counterintuitive. Indeed, EGF is
Fig. 4 (See legend on next page.)
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Fig. 4 Functional comparison of human aHSCs and rHSCs. a EdU staining images showing the influence of RM on basal and PDGF-BB-induced HSC
proliferation. b The percentage proliferative cells, calculated as the ratio of EdU-positive nuclei over the total (DAPI) nuclei. c The PDGF-BB (20 ng/mL)
induced fold change in proliferation for aHSCs and rHSCs, relative to their basal condition. d Fluorescent images depicting the basal and TGFβ-induced
(10 ng/mL) proteolytic digestion (green) of the fluorescein-labeled gelatin substrate by aHSCs and rHSCs. e The quantified basal and TGFβ-induced
matrix metalloproteinase activity of aHSCs and rHSCs presented as the percentage green stained area over the total image area. f The PDGF-BB-
inducible migration of aHSCs and rHSCs was assessed in a transwell migration assay. The aHSCs and rHSCs were seeded in collagen-coated Boyden
chambers and stimulated with PDGF-BB (20 ng/mL) or with its solvent as a control, in the lower compartment. Results are presented as the number of
migrated cells in each condition. The presented results are from three different donors. ns not significant, p≥ 0.05, *p < 0.05
El Taghdouini et al. Fibrogenesis & Tissue Repair  (2015) 8:14 Page 8 of 15overexpressed in the fibrotic liver [25], plays a central
role during liver regeneration [26], and is member of a
186-gene signature predictive of progressive cirrhosis,
hepatocellular carcinoma, and death in patients with
cirrhosis [27]. Moreover, the pharmacological inhibition
of the EGF receptor was shown to attenuate liver fibrosis
[28]. However, to our knowledge, the present study is
the first one to address the direct effect of EGF stimula-
tion on the expression of activation markers in human
primary HSCs. We find that FGF2, another growthFig. 5 Gene expression changes elicited during the in vitro reversion of hum
genes significantly differentially regulated between aHSCs, qHSCs, and rHSCs.
regulated between qHSCs and rHSCs or aHSCs and rHSCs. The intersection of
differentially regulated in both comparisons. c List of fold changes (relative to
(microarray data). d Confirmation of the expression levels of selected top dere
donors. **p < 0.01, ***p < 0.001factor known to be overexpressed in the fibrotic liver
[29], synergized the negative regulation of ACTA2 and
LOX expression by EGF. Although this synergistic effect
was not very pronounced, it was consistent in HSCs
isolated from patients with different backgrounds (i.e.,
age and gender). A synergy between EGF and FGF2 in
the negative regulation of human HSC activation has
not been shown yet; however, a previous study already
showed that EGF and FGF2 can act synergistically to in-
crease the proliferation of neural precursor cells [30].an HSC activation. a Heatmap representing the hierarchical clustering of
b Venn diagram showing the number of genes significantly differentially
the Venn diagram shows the number of overlapping genes significantly
aHSCs) for the top 10 genes upregulated and downregulated in rHSCs
gulated genes by RTq-PCR. The presented results are from three different
Fig. 6 Gene expression changes during in vitro reversion of human primary HSCs inversely correlate with changes observed during in vitro HSC
activation. a Venn diagram showing the number of genes differentially regulated during HSC activation ([qHSCs vs aHSCs], p≤ 0.05 and fold change
≥2) and the number of genes differentially regulated during in vitro reversion to quiescence-like ([aHSCs vs rHSCs], p≤ 0.05 and fold change ≥2). The
intersection of the Venn diagram shows the number of overlapping genes between both comparisons. b Expression heatmap for the genes that are
significantly upregulated during HSC activation and significantly downregulated during reversion to quiescence-like. c Profile plot showing the
expression profile of ACTG2 expression in qHSCs, aHSCs, and rHSCs as illustration for the 148 genes showing a similar expression profile. d The top five
Gene Ontology (GO) terms and KEGG pathways associated with the set of genes represented in (c). e Expression heatmap for the genes that are
significantly downregulated during HSC activation and significantly upregulated during reversion to quiescent-like cells. f Profile plot showing the
expression profile of NFKBIA expression in qHSCs, aHSCs, and rHSCs as illustration for the 64 genes showing a similar expression profile. g The top five
GO terms and KEGG pathways associated with the set of genes represented in (f)
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EGF responsiveness, providing a possible explanation for
our observation. We also find that a mix of palmitic
acid and retinol induces the formation of retinyl ester-
containing intra-cytoplasmic lipid droplets in human
HSCs. This is in concordance with previous work by Lee
et al. showing that palmitate induces the upregulation of
ADRP, a lipid droplet associated protein, and that this ef-
fect was potentiated by retinol in human HSCs [31]. We
find that adding oleic acid further increased the number
of lipid droplets and lipid droplet-positive cells induced
by retinol and palmitic acid (data not shown). Interest-
ingly, although the combination of oleic acid, palmiticacid, and retinol only has a subtle effect on the expres-
sion of activation markers, it strongly potentiates the
effect of EGF and FGF2 on the reduced expression of
ACTA2, COL1A1, and LOX. Although not all cells incor-
porated lipid droplets and around 30 % of the cells
remained UV−, no difference was found in the overall
expression levels of the different activation markers
between UV+ and UV− rHSCs. This indicates that HSCs
are heterogeneous in their capacity for retinoid and lipid
storage, corroborating previous studies by D’Ambrosio
et al. [19]. Furthermore, it suggests that the potentiated
effect observed for RM is not dependent on the presence
of retinyl ester-containing lipid droplets.
Table 2 Overview of the fold difference in mRNA expression
levels of in vivo iaHSC signature genes in rHSCs and aHSCs
Fold change rHSC vs aHSC
Gene Accession Donor L4 Donor L8 Donor L12
CXCL1 NM_001511 52 30.7 26
CXCL2 NM_002089 39.1 7.3 23.6
CXCL10 NM_001565 3.7 32.7 nd
CTSS (tv2) NM_001199739 27.6 20.5 10.1
LY86 NM_004271 1.8 26.4 6.2
CAPN6 NM_014289 2.6 5.2 14.1
RND1 NM_014470 1.9 11.7 6.6
KRT20 NM_019010 6 nd 3.9
CX3CR1 (tv1) NM_001171174 3.2 nd 5.4
GPC3 (tv4) NM_001164619 1.5 1.8 1.2
tv transcript variant, nd not detected
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the activated phenotype of HSCs isolated from a cirrhotic
patient, the therapeutic relevance of this finding remains
to be demonstrated. Indeed, the experimental use of
in vivo activated human HSCs necessitates their culture
expansion, during which the cells are exposed to the same
artificial environment as the in vitro activated HSCs used
in the present study. Although not shown for human
HSCs yet, we recently demonstrated that the gene expres-
sion profile of mouse HSCs is significantly altered as soon
as 10 h after in vitro culture [32, 33]. Therefore, we believe
that even a relatively short-term culture expansion of
in vivo aHSCs will result in a deregulated gene expression
profile that is not necessarily representative of the in vivo
situation anymore. In addition to a reversion of the
activated phenotype, we show that RM can prevent the
culture-induced activation of qHSCs. Because human
qHSC isolations are characterized by modest yields and
freshly isolated cells are culture expanded during which
they quickly acquire an activated phenotype, these experi-
ments were performed on freshly isolated mouse qHSCs.
Microarray analysis of non-cultured human qHSCs
and in vitro aHSCs and rHSCs reveals that the global
gene expression profile of rHSCs was still very similar to
that of aHSCs, indicating that this reversal in phenotype
is not substantiated by a thorough reprogramming at the
transcriptional level. Indeed, our study found only 375
genes to be differentially regulated between rHSCs and
aHSCs. Although this corresponds to only 1.8 % of all the
genes represented on the HGU219 array, ~75 % of these
genes are also differentially regulated during activation
and over 56 % show an expression profile that negatively
correlates during activation and reversion. The major part
of those genes is upregulated and again downregulated
during activation and reversion, respectively, and is
enriched for genes that are involved in pathways that areknown to play major roles in aHSCs such as “Vascular
smooth muscle contraction” and “Focal adhesion”. There-
fore, changes in expression of these genes probably
underpin the observed shift in HSC phenotype. Inter-
estingly, serum response factor (SRF) and specificity
protein 1 (SP1) were predicted to be the transcription
factors with the highest importance and occurrence
score, respectively, for the binding of common regulatory
elements for this set of genes (http://dire.dcode.org/). SRF
is mainly involved in cell differentiation by regulating
genes that control cell growth, cytoskeletal organization,
contractility, and motility [34]. In rodent HSCs, Srf ex-
pression was shown to be inducible by TGFβ and small
interfering RNA (siRNA)-mediated knockdown of Srf re-
sulted in the downregulation of Acta2 expression [35].
SP1, a member of the Krüppel-like family that was shown
to have an increased DNA binding activity in aHSCs,
co-operates with Krüppel-like factor 6 (KLF6) to induce
the expression of TGFβ and urokinase plasminogen ac-
tivator (uPA), which promotes the activation of latent
TGFβ [36, 37]. Other pro-fibrogenic genes regulated
by SP1 include Col1a2 and Timp1 [38, 39]. In rodent
models of kidney, lung, and liver fibrosis, SP1 targeting
was shown to be a powerful anti-fibrotic strategy [40].
This anti-fibrotic effect is presumably due to the
abrogation of SP1 activity in myofibroblasts, as it was
shown that SP1 targeting inhibits the expression of pro-
fibrogenic genes as well as proliferation in rat aHSCs [41].
Future research will show whether targeting of both these
transcription factors in fibrotic patients might represent a
therapeutic strategy to revert the activated phenotype of
human HSCs.
In inverse analogy to the differentiation of adipocytes
from pre-adipocytes, anti-adipogenic regulation has been
shown to underlie HSC activation [42]. Because both
oleic acid and palmitic acid are reported to stimulate
adipocytic differentiation [43], we speculate that they
potentiate the negative effect of EGF and FGF2 on the
expression of activation markers by enforcing the
transdifferentiation of human aHSCs towards the more
adipogenic qHSC phenotype. The loss of PPARγ activ-
ity, the master regulator of adipogenesis, has been
found to play an important role during HSC activation
[44–46], and overexpression in activated HSCs has
been shown to induce a phenotypic switch to a more
quiescent-like phenotype [11]. Surprisingly, the adipo-
genic phenotype of rHSCs was not supported by an
increased expression of PPARγ and its downstream
effector genes. Recent studies show that PPARγ induc-
tion is a multistep process, necessitating both epigenetic
reconfiguration [47, 48] and chromatin remodeling [49].
Furthermore, transcriptional activities of PPARγ have
been shown to require chromatin presetting [50], and in
turn, PPARγ can lead to post-translational histone
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maintain the adipogenic transcription program. Seem-
ingly, the adipogenic cue provided by RM or the treatment
duration is an insufficient trigger for this multistep
process to take place in activated primary human HSCs.
Nevertheless, we find that RM induces the expression of
ADRP (Additional file 1: Figure S7), a protein known to
be expressed early during adipogenesis and previously
shown to be sufficient to stimulate lipid droplet formation
and accumulation independently of PPARγ or other
lipogenic genes [52]. Moreover, work by Lee et al. previ-
ously demonstrated a role for palmitic acid and retinol
in upregulating the expression of ADRP [53] in LX-2
cells, an immortalized human HSC line. The authors
report that the treatment correlated with reduced
ACTA2 and COL1A1 expression and ADRP knockdown
abrogated the treatment’s effect [53]. In contrast, our
experiments do not reveal a direct role for ADRP in the
negative regulation of activation genes. Nevertheless,
increased ADRP expression provides a possible explan-
ation for the potentiating effect of the dietary supple-
ments on the downregulation of ACTA2, COL1A1, and
LOX by EGF and FGF2.
At the functional level, we show the RM’s potency to
not only reduce basal proliferation and MMP activity of
the cells, but also to actively counteract the increased
functionality of HSCs by well-known pro-fibrogenic
factors. The mechanism underlying these effects how-
ever remains unknown and needs further attention.
Recently, Kisseleva et al. for the first time described
the unique phenotypic characteristics of murine in vivo
iaHSCs and identified a set of genes highly expressed in
iaHSCs compared to qHSCs and/or aHSCs [13, 15].
Interestingly, we find that these genes were consistently
upregulated in rHSCs, derived from different donors.
Although the relevance of this observation remains to
be demonstrated, their increased expression in in vitro
reverted human HSCs suggests also a potential role for
these genes in promoting a quiescent-like phenotype in
human HSCs.
Conclusions
In conclusion, this study for the first time provides evi-
dence that human HSCs can be reverted to a quiescent-
like state and provides a first phenotypic and genomic
characterization of in vitro reverted human HSCs.Methods
Patient samples
The protocol and experiments were approved by the
ethical committees of St-Luc Hospital and the Faculty of
Medicine of Université Catholique de Louvain. An
agreement from the Belgian Ministry of Health wasobtained for the Hepatocytes and Hepatic Stem Cells
Bank. A written and signed informed consent has been
obtained for each human liver used in the current study.
Five livers, for which the clinical characteristics are
summarized in Table 1, were used in the current study.
Additionally, commercially available primary human
liver myofibroblasts derived essentially from hepatic
stellate cells and portal fibroblasts (Tebu-Bio NV, Antwerp,
Belgium) was used.
Isolation and in vitro reversion of human activated HSCs
Human aHSCs were obtained by plating the qHSC-
enriched population obtained after Nycodenz (Myegaard,
Oslo, Norway) gradient centrifugation of the non-
parenchymal cell fraction [54]. Homogeneous populations
of aHSCs were obtained after three passages in Dulbecco’s
modified Eagle’s medium (DMEM) supplemented with
10 % FBS at 37 °C in a humidified atmosphere with 5 %
CO2 and subsequently cultured in 1 % FBS supplemented
medium. Prior to each passage, cells were washed with
phosphate buffered saline (PBS) and lifted using 0.05 %
trypsin (Lonza). For reversion of the activated phenotype,
human aHSCs were seeded at a density of 10,000 cells/
cm2 (unless stated differently), and 24 h later, the cells
were washed and incubated with DMEM supplemented
with 1 % FBS, 20 ng/mL epidermal growth factor (EGF)
(Peprotech, London, UK), 10 ng/mL fibroblast growth
factor 2 (FGF2) (Peprotech), 100 μM oleic acid (Sigma),
100 μM palmitic acid (Sigma), and 5 μM retinol (Sigma).
The medium was refreshed every 2 days for 5 days, and
the cells were harvested for further analysis on day 6.
Isolation of non-plated human quiescent HSCs
The human liver parenchymal and non-parenchymal cell
fractions were separated from each other by sequential
perfusion of liver pieces with pre-warmed EGTA-
containing EBSS medium (Lonza, Verviers, Belgium)
and a digestion enzyme solution (EBSS supplemented
with 0.9 mg/mL collagenase P and 0.03 mg/mL soybean
trypsin inhibitor (Roche)) for 9 to 12 min. Collagenase
digestion was stopped with ice-cold M199 wash medium
(Lonza) containing 0.03 mg/mL of soybean trypsin
inhibitor and 100 mL/L of human plasma [55]. After
filtration, the non-parenchymal cells were separated
from the parenchymal cells by subsequent low-speed
centrifugation steps (50g) and submitted to an additional
centrifugation step (640g). Non-parenchymal cell pellets
were then resuspended and cryopreserved in DMEM
(Lonza) supplemented with 20 % FBS (Biochrom GmbH,
Berlin, Germany) and 5 % dimethyl sulfoxide (DMSO)
(Sigma, St. Louis, MO, USA). The isolation of high-
purity human qHSCs was performed as described previ-
ously [56]. In brief, dissociated and washed single non-
parenchymal cells were suspended in a 5 % FBS, 2mM
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anti-CD32 (Abcam, Cambridge, UK) and anti-CD45 (BD
Biosciences, San Jose, CA, USA). 7-Aminoactinomycin
(7-AAD) (eBioscience, San Diego, CA, USA) was used
for the exclusion of non-viable cells. Pure populations
of qHSCs were sorted as CD32−CD45−UV+ cells, using
FACSAria™ (BD Biosciences). RNA from freshly isolated
qHSCs was obtained using RNeasy Micro Kit (Qiagen).
RNA samples were amplified using the Ovation Pico
WTA system V2 (NuGEN).
Mouse HSCs were isolated from male BalbC mice
(age 20–25 weeks) (Charles River Laboratories,
L’arbresle, France) and cultured in DMEM with 10 %
FBS, as described previously [57]. For treatment experi-
ments with mouse HSC reverting medium (mRM)
(DMEM supplemented with 10 % FBS, 40 ng/mL EGF,
20 ng/mL FGF2, 100 μM oleic acid, 100 μM palmitic
acid, and 5 μM retinol), freshly isolated mouse qHSCs
were seeded at a density of 7.500 cells/cm2. The inhib-
ition of activation was assessed by relative comparison
to control cells cultured in DMEM supplemented with
10 % FBS for the same period of time. All procedures
on animals were carried out in accordance with the
University’s guidelines for the care and use of labora-
tory animals in research. The performed experiments
were approved by the ethical committee of the Vrije
Universiteit Brussel in project 12-212-1.
Gene expression profiling and analysis
Total RNA originating from cultured (activated and
reverted HSCs; n = 3 from corresponding donors) and
uncultured (FACS-sorted quiescent HSCs; n = 3 from two
corresponding donors) primary human HSCs was isolated
by using RNeasy Micro Kit (Qiagen GmbH, Hilden,
Germany) following the manufacturer’s recommendations.
Total RNA concentration and quality control was assessed
using RNA 6000 Pico Kit (Agilent, Santa Clara, CA, USA).
RNA samples were amplified by using Ovation PicoSL
System V2 (NuGene Technologies, CA, USA) and EN-
CORe Biotin module (NuGene Technologies). Amplified
and purified RNA samples were labeled and hybridized to
the Affymetrix HG-U219 GeneChip (Affymetrix, Santa
Clara, California, USA). Data normalization and analysis
was performed using GeneSpring GX12 (Agilent, Santa
Clara, CA, USA) as described previously [32]. Briefly,
Affymetrix gene expression data were normalized using
the robust multi-array algorithm [58]. For the detection of
differentially expressed genes, a p value cutoff of 0.05 was
used in combination with a fold change cutoff of 2.0.
Functional analysis of gene expression data (gene ontology
(GO) and Kyoto Encyclopedia of Genes and Genomes
(KEGG) pathways) was conducted using an open access,
high-level cross-platform microarray dataset analysis tool
(InCroMAP) (http://www.ra.cs.uni-tuebingen.de/software/InCroMAP/). Raw data are made publically available on
the NCBI Gene Expression Omnibus database, with acces-
sion number GSE68001.
Immunocytochemistry
Nycodenz-isolated HSCs cultured for 1 day or for three
passages were washed with PBS and fixed for 10 min
with 4 % buffered formaldehyde (Merck, Darmstadt,
Germany). Following permeabilization with 0.1 % Triton
X-100 (in PBS containing 1 % bovine serum albumin),
cells were incubated overnight with anti-αSMA (1/1000)
(Sigma). Primary antibody binding was visualized using an
Alexa488-labeled secondary antibody (1/200) (Invitrogen,
Eugene, OR, USA). Images were taken with an AxioCam
MRc5 digital camera (Carl Zeiss). NCAM1, nestin, and
desmin stainings were performed as described previously
[59]. Briefly, the cells were fixed, endogenous peroxidase
was eliminated, and cells were permeabilized using PBS
containing 1 % Triton X-100 (Sigma). Thereafter, the
cells were blocked by 1-h incubation in PBS containing
1 % bovine serum albumin (Sigma), incubated with
primary anti-NCAM1 (1/100) (Abcam), anti-Nestin
(1/1000) (Abcam), or anti-Desmin (1/50) (Abcam) for
1 h, washed and incubated with secondary antibody
(Envision, Dako) for 30 min. Detection was performed
after 5 min incubation with liquid DAB and substrate
chromogen (Dako). Counterstaining was performed
using Mayer’s hematoxylin for 10 min. Preparations
were then mounted for microscopic analysis (DMIL, Leica,
Belgium).
Lipid staining
The cells were washed with PBS and fixed in 10 %
formalin solution. The cells were then washed with
deionized water, incubated with isopropanol for 5 min,
and stained with diluted (3/2 in water) and filtered Oil
Red O (0.3 % (w/v) in 99 % isopropanol) (Sigma) for
20 min. The red-stained lipid droplets were visualized
with light microscopy (Carl Zeiss).
Western blot
Cells were washed with ice-cold PBS and scraped with
ice-cold lysis buffer (170 mM NaCl, 10 mM EDTA,
50 mM Tris pH 7.4, 50 mM NaF, 0.2 mM dithiothreitol,
and 0.5 % NP-40) supplemented with protease (Roche
Diagnostics, Mannheim, Germany) and phosphatase
(Roche Diagnostics) inhibitors. Protein concentrations
were determined using the BCA protein assay kit (Pierce
Chemical Co, Rockford, IL, USA). Fifteen microgram of
protein was separated on a 8 % Tris-glycine SDS-
polyacrylamide gel and electroblotted onto polyvinyli-
dene difluoride membranes (Amersham Biosciences,
Little Chalfront, UK) using a wet blotting apparatus
(Mini Trans-Blot Cell, BioRad, Nazareth, Belgium). Blots
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saline (TBS) with 0.2 % Tween (Sigma) and subse-
quently incubated overnight with primary anti-PDGFRβ
(diluted 1/1000 in blocking buffer) (Abcam), anti-αSMA
(1/50) (Dako), anti-COL1A1 (1/1000) (Abcam), or anti-
GAPDH (diluted 1/30,000) (Abcam). The membranes
were washed and incubated with a horseradish peroxidase-
conjugated secondary antibody (1/20,000) (Dako, Glostrup,
Denmark) for 1 h, and the antigen was visualized by
enhanced chemiluminescence using ECL substrate (Pierce
Chemical Co.).
Proliferation assay
Cell proliferation of human HSCs was assessed with the
Click-iT EdU Cell Proliferation Assay Kit (Invitrogen,
Eugene, OR, USA). HSCs were cultured under control
conditions or in RM for 6 days. On day 6, the cells
were labeled with 10 μM EdU for 6 h and subse-
quently formalin fixed and mounted with Prolong
Gold antifade reagent with DAPI (Invitrogen). EdU
incorporation was visualized according to the manu-
facturer’s instructions. The percentage proliferation
was calculated as the ratio of EdU-positive cells to
DAPI-positive cells. For the PDGF-BB stimulation ex-
periments, the control medium and RM were supple-
mented with 20 ng/mL human recombinant PDGF-BB
for 48 h prior to EdU labeling. The quantification was
performed on at least 500 cells per donor and is pre-
sented as the mean percentage measured in three dif-
ferent donors.
In situ zymography
The matrix metalloproteinase activity of human HSCs
was assessed using the highly quenched, fluorescein-
labeled pig skin gelatin (DQ™ gelatin) (Invitrogen).
Upon proteolytic digestion, its green fluorescence is
revealed and can be used to measure enzymatic activ-
ity. A 1 mg/mL stock solution of DQ gelatin was pre-
pared using deionized water and stored at 4 °C. Prior
to cell seeding (20,000 cells/cm2), glass coverslips
(12 mm diameter) were coated with 50 μg DQ gelatin
for 1 h. Twenty-four hours post-seeding, the cells were
washed with serum-free DMEM and cultured for 6 days
under control conditions or RM. On day 6, the cells
were formalin fixed and mounted with Prolong Gold
antifade reagent with DAPI. The percentage green stained
area was calculated using ImageJ (http://imagej.nih.gov/ij/
index.html). For the TGFβ stimulation experiments,
the control medium and RM were supplemented
with 10 ng/mL human recombinant TGFβ for 48 h
prior to being fixed and analyzed. The quantification
was performed on 5–10 images per donor and is
presented as the mean percentage measured in five
different donors.Migration assay
Both aHSCs and rHSCs were seeded in collagen-coated
Boyden chambers (Millipore) (40,000 cells/chamber) in
serum-free DMEM. After 60 min, the chambers were
transferred to wells with 20 ng/mL PDGF-BB (R&D
Systems, Minneapolis, MN, USA) or its solvent as a con-
trol. After 16 h, non-migrated cells were cleared and
migrated cells were fixed with ice-cold 100 % methanol
and mounted with Prolong Gold antifade reagent with
DAPI. The quantification was performed by manually
counting the totality of migrated cells on images cover-
ing the entire membrane and is represented as the mean
of three different donors.
Viability/cytotoxicity assay
For the LIVE/DEAD viability/cytotoxicity assay (Life
Technologies), aHSCs and rHSCs were incubated with
PBS containing 4 μM ethidium homodimer and 2 μM
calcein for 15 min at 37 °C, washed thoroughly with
PBS, and subsequently analyzed under a fluorescent
microscope (Carl Zeiss). Images were taken with an
AxioCam MRc5 digital camera (Carl Zeiss).
RNA purification and RTq-PCR
RNA was extracted and purified from cultured and
uncultured cells using the ReliaPrep RNA Cell Miniprep
System (Promega, Madison, WI, USA). Total RNA was
converted to cDNA by reverse transcription using the
Revert Aid Kit (Thermo Fisher Scientific, St. Leon-Rot,
Germany). Quantitative real-time polymerase chain
reaction was performed using the GoTaq qPCR Master
Mix with BRYTE green (Promega). A 7500 real-time PCR
system was used and data was analyzed using System SDS
software v2.0.6 (Applied Biosystems). Fold change differ-
ences between samples were determined using the
comparative Ct method (ΔΔCt). The expression level of dif-
ferent target genes, relative to glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) and the calibrator, was given by
2-ΔΔCt. Gene-specific primers were produced by Inte-
grated DNATechnologies (Leuven, Belgium).
Statistical analysis
GraphPad Prism v4.0.0 (GraphPad Software, La Jolla, CA,
USA) was used for statistical analysis. Data in the figures
are expressed as means ± SEM. Differences among groups
were tested for statistical significance by Student t test or
analysis of variance (ANOVA) followed by Tukey’s test,
depending on the number of groups (ns = not significant,
p ≤ 0.05, *p < 0.05, **p < 0.01, ***p < 0.001).
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